The English approach to obviousness - It all depends on the facts? By Darren Smyth on Thursday, September 22, 2016 Court of Appeal Genentech herceptin Hospira inventive step obvious to try reasonable expectation of success trastuzumab would/could +
What the pH? A closer look at Hospira v Cubist and daptomycin micelles By Darren Smyth on Friday, September 02, 2016 Cubist daptomycin Hospira micelle obviousness pH +
Hospira v Genentech - revocation of patents confirmed on appeal By Darren Smyth on Friday, July 29, 2016 amendment breast cancer Court of Appeal Genentech herceptin Hospira inventive step product-by-process claims revocation trastuzumab +
Letter from AmeriKat: Hospira's Angiomax win, Apple jury award vacated & Obama's Pacific trade deal By Annsley Merelle Ward on Sunday, July 12, 2015 AmeriKat apple generic pharma products Hospira jury awards smartphones trade deals Trans-Pacific Partnership Agreement US patent damages us patent litigation +
Patent Déjà vu - Hospira v Genentech and another patent dies By Darren Smyth on Tuesday, June 30, 2015 Genentech herceptin Hospira inventive step novelty revocation trastuzumab +
Hospira v Genentech Mark 1, the Appeal By Darren Smyth on Friday, February 06, 2015 breast cancer Genentech herceptin Hospira inventive step novelty revocation trastuzumab +
Hurray for judicial sense on product by process claims - Birss triumphs in Hospira v Genentech By Darren Smyth on Wednesday, December 10, 2014 amendment breast cancer Genentech herceptin Hospira inventive step product-by-process claims revocation trastuzumab +
UPDATE: Birss J refuses permission to appeal in Genentech's Herceptin battle By Annsley Merelle Ward on Friday, May 23, 2014 AmeriKat appeal dosage regime patents formulation patents Genentech Hospira interim costs mr justice birss revocation +
Another two bite the dust – Hospira v Genentech By Darren Smyth on Monday, April 14, 2014 breast cancer declaration of non-infringement Genentech herceptin Hospira insufficiency inventive step novelty revocation trastuzumab +
Sanofi Aventis Taxotere Patents invalidated by CAFC By Darren Smyth on Tuesday, April 10, 2012 Apotex docetaxel Hospira inequitable conduct paclitaxel Sanofi-Aventis taxane +